PR Newswire
WILMINGTON, Del., Feb. 12, 2026
Increase in prevalence of chronic diseases, surge in the adoption of strategies by key players, and rise in R&D activities in the radiopharmaceuticals sector drive the growth of the global radiopharmaceuticals market. However, high costs related to development and implementation of radiopharmaceuticals hampers the market growth. Moreover, increase in the number of pipeline products is expected to offer lucrative opportunities in the coming years.
WILMINGTON, Del., Feb. 12, 2026 /PRNewswire/ — According to a new report published by Allied Market Research, titled, «Radiopharmaceuticals Market by End User, Radioisotope, Application, and Type: Global Opportunity Analysis and Industry Forecast, 2024-2033». According to the report, the radiopharmaceuticals market was valued at $7.9 billion in 2023 and is estimated to reach $21.8 billion by 2033, growing at a CAGR of 10.6% from 2024 to 2033.
https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg
Radiopharmaceuticals are medications or drugs that contain radioactive isotopes. They are used in nuclear medicine imaging tests for diagnosis and treatment. They help visualize physiological functions, which helps diagnose conditions such as cancer, cardiovascular diseases, and neurological disorders.
Request Sample of the Report on Global Radiopharmaceuticals Market 2033 –
https://www.alliedmarketresearch.com/request-sample/A14458
They play a crucial role in medical imaging and targeted therapies for various diseases. The targeted therapy minimizes damage to surrounding healthy tissues. This is particularly important in cancer treatment, where precision is vital. They allow healthcare providers to treat certain conditions and are termed as therapeutic radiopharmaceuticals, which is a relatively new field with ongoing research to study their uses.
Increase in the prevalence of chronic disease, surge in investments for R&D, growth in demand for sophisticated healthcare facilities, and rise in healthcare expenditure drive the radiopharmaceuticals market growth. However, side effects and high cost of implementation and development of radiopharmaceuticals hamper the growth of the radiopharmaceuticals market.
By application, the cancer segment accounted for a major share in the radiopharmaceutical market in 2023 and is expected to witness the highest CAGR during the forecast period owing to rise in prevalence of cancer, increase in technological advancements, and rise in oncology care investment. In addition, rise in adoption of personalized medicine approaches in oncology, owing to advancements in genomics, molecular profiling, and biomarker identification, is boosting the demand for customized therapeutic strategies, including radiopharmaceutical-based precision oncology.
By radioisotope, the Technetium 99m segment dominated the radiopharmaceuticals market size in 2023 and is expected to register the highest CAGR during the forecast period as it is the most widely used radioisotope in nuclear medicine due to its favorable characteristics such as suitable physical properties and compatibility with a variety of radiopharmaceutical formulations.
Want to Explore More, Connect to our Analyst –
https://www.alliedmarketresearch.com/connect-to-analyst/A14458
Key Findings of the Radiopharmaceuticals Market
- By application, cancer is one of the dominating segment in the market and accounted for the revenue share of over 52.2% in 2023.
- By type, the Technetium 99m segment is the dominant segment in the market in 2023.
- By end user, the hospitals and clinics segment dominated the radiopharmaceuticals market size in 2023 and is anticipated to grow at the highest CAGR during the forecast period.
- Region wise, the radiopharmaceuticals industry in North America held a significant share of over 40% in 2023.
North America to maintain its dominance by 2033
North America accounted for the largest share in the radiopharmaceuticals market and is expected to remain dominant during the forecast period owing to advanced healthcare infrastructure and well-established pharmaceutical industry in the region, which facilitates the production, development, and distribution of radiopharmaceuticals. In addition, favorable regulatory policies and supportive frameworks for reimbursement promote R&D in radiopharmaceuticals, which drives the radiopharmaceuticals market growth in this region. However, Asia-Pacific is expected to register the highest CAGR during the forecast period owing to rise in healthcare infrastructure coupled with growing investments in hospitals, research facilities, and diagnostic centers, and surge in prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions.
How Do Government Policies and Regulations Impact Regional Market Growth?
Government policies and regulations significantly influence regional growth in the radiopharmaceutical sector through multiple mechanisms. Regulatory frameworks governing the production, distribution, and clinical use of radioactive materials directly impact market accessibility and development timelines. Stringent approval processes established by agencies such as the FDA in the United States, EMA in Europe, and PMDA in Japan determine how quickly radiopharmaceuticals can enter the market, affecting regional competitiveness.
Reimbursement policies play a crucial role in market adoption, as favorable coverage decisions by government healthcare programs encourage clinical utilization and investment in radiopharmaceutical development. Conversely, restrictive reimbursement frameworks can limit market penetration despite clinical efficacy.
Nuclear medicine regulations, including licensing requirements for handling radioactive materials and operational standards for production facilities, create barriers to entry that vary significantly across regions. Countries with streamlined regulatory pathways and supportive infrastructure tend to attract greater investment and experience accelerated market growth.
Additionally, government initiatives promoting nuclear medicine research, funding for cyclotron facilities, and investment in healthcare infrastructure directly impact regional market expansion. Trade policies affecting the import and export of radioactive isotopes further influence supply chain dynamics and market accessibility.
Regions with comprehensive regulatory frameworks that balance safety requirements with innovation incentives typically demonstrate stronger market growth, while those with ambiguous or overly restrictive policies may experience slower adoption and limited development of radiopharmaceutical capabilities.
For Purchase Related Queries/Inquiry –
https://www.alliedmarketresearch.com/purchase-enquiry/A14458
How Do Different Product Types or Categories Compare in Performance?
BY type, the radiopharmaceutical market is bifurcated into diagnostic and therapeutic. Diagnostic radiopharmaceuticals, particularly PET tracers such as F-18 FDG, dominate the market due to wide range of oncology applications, established clinical protocols, disease detection, characterization, and monitoring across various medical specialties. Their versatility and cost-effectiveness across cardiology and bone imaging also boost their demand in the market.
Therapeutic radiopharmaceuticals exhibit rapid growth owing to advancements in targeted radionuclide therapy in oncology, which particularly include alpha and beta-emitting agents for treating prostate cancer and neuroendocrine tumors. In addition, theranostic radiopharmaceuticals is witnessing ongoing research, which combines diagnostic and therapeutic capabilities. Short half-life products require proximity to production facilities, while longer-lived isotopes enable broader regional distribution, directly impacting market accessibility and commercial performance across categories.
Get Customized Reports with your Requirements –
https://www.alliedmarketresearch.com/request-for-customization/A14458
Competitive Landscape
- South African Nuclear Energy Corporation (Necsa)
- Eckert & Ziegler
- PRECIRIX
- Nihon Medi-Physics Co. Ltd
- Isotopia Molecular Imaging
- Fusion Pharmaceuticals Inc.
- Actinium Pharmaceuticals, Inc.
- Lantheus
- Bayer AG
- Cardinal Health
- Eczacibasi
- ITM Isotope Technologies Munich SE
- The State Atomic Energy Corporation ROSATOM
- Bracco
- SOFIE
- Clarity Pharmaceuticals
- NorthStar Medical Radioisotopes
- Telix Pharmaceuticals Limited
- GE Healthcare
- Curium Pharma
- Novartis AG
- Jubilant Pharmova Limited
- Eli Lilly and Company
Trending Reports in Healthcare Industry:
Immunostimulant Market – Global Opportunity Analysis and Industry Forecast, 2024-2035
Dyspnea Treatment Market – Global Opportunity Analysis and Industry Forecast, 2024-2035
Breast Fillers Market – Global Opportunity Analysis and Industry Forecast, 2024-2035
Molecular Spectroscopy Market – Global Opportunity Analysis and Industry Forecast, 2024-2035
Wound Irrigation System Market – Global Opportunity Analysis and Industry Forecast, 2024-2035
Herb Extract Market – Global Opportunity Analysis and Industry Forecast, 2024-2035
Digital Radiology/Radiography Market – Global Opportunity Analysis and Industry Forecast, 2024-2035
Hearing Care Devices Market – Global Opportunity Analysis and Industry Forecast, 2024-2030
Intravenous (IV) Therapy and Vein Access Market – Global Opportunity Analysis and Industry Forecast, 2024-2030
AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model) Offered by Allied Market Research:
AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail themselves of an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.
Get access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access
About Allied Market Research:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of «Market Research Reports» and «Business Intelligence Solutions.» AMR has a targeted view to provide business insights and consulting to assist its clients in making strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.
We are in professional corporate relations with various companies, and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality data and help clients in every way possible to achieve success. Each data presented in the reports published by us is extracted through primary interviews with top officials from leading companies in the domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact
David Correa 1209 Orange Street,Corporation Trust Center,Wilmington, New Castle,Delaware 19801 USA.Toll Free: +1-800-792-5285Int’l: +1-503-894-6022UK: +44-845-528-1300Hong Kong: +852-301-84916India (Pune): +91-20-66346060Fax: [email protected] Web: https://www.alliedmarketresearch.com
Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/radiopharmaceuticals-market-to-reach-21-8-billion-by-2033-globally-at-10-6-cagr-allied-market-research-302686492.html
Tengo varias preguntas sobre esto a ver si me podiais aclarar:
-¿Puedo hacer un ingreso regular de 800 euros y me cobran 0euos de comisiones y mto.?
-¿Puedo sacar el dinero cuando quiera?,¿todo ó tengo entendido que hay que mantener un mínimo de 100 euros los 30 meses?
-No necesito pero me obligan a sacar una tarjeta de débito que me cuesta 11 euros el primer año y 22 euros la renovación, también otra de credito que me cuesta 0 euros el primer año y 35 euros la renovación.
¿Hay que mantenerlas 13 meses?
¿Puedo cancelar alguna de ellas desde el principio?
¿Puedo cancelar alguna de ellas antes de la renovación?
¿Hay alguna tarjeta de credito más barata?
Aparte de la cuenta nómina he visto que también que para que te den la tv también se puede sacar una cuenta tarifa plana básica o personal, ¿sabeis algo de estas cuentas?¿que requisitos tienen?
Muchas gracias a todos por responder
Yo fui a informarme y te cuento. Únicamente admiten los ingresos regulares en el caso de que seas autónomo. Te abren una cuenta Tarifa Plana Cero que está exenta de comisiones y presenta alguna ventaja más. Sobre dejar un mínimo de saldo en la cuenta no es necesario, pero sí te obligan a mantener varias tarjetas durante los 30 meses con un coste aproximado de 100 euros anuales.
hola buenas!
me llamo javi y estoy dudando de que banco, me puede dar mas beficios, sin sorpresas por domiciliar la nomina, ya que llevo años en la caixa y no me da nada ningun beneficio. es mas me rechazan los prestamos que solicito, ni siquiera una targeta de credito, por alegan de que siempre esta a cero la cuenta, yo cuando cobro la nomina dejo el dinero para los pagos, y saco el resto, pues no me fio, de que un dia me quede sin dinero, ya que esta todo muy mal, corre riesgo mi dinero o mis ahorros en el banco?? muchas gracias y un cordial saludo.
javi
NO TE EXTRAÑE QUE NO TE DEN LOS PTMOS, PORQUE LO QUE VEN ES QUE NO TIENES CAPACIDAD DE AHORRO PORQUE SIEMPRE DEJAS LA CTA. EN MINIMOS, ASI NINGUN BANCO TE LO VA A CONCEDER. TAMBIEN ES VERDAD QUE LA CAIXA, COMO TANTAS OTRAS CAJAS, TIENE EL PUÑO CERRADO PARA LOS RIESGOS, PARA REMONTAR. NO TE PREOCUPES, QUE POR UNA NOMINA NO CREO QUE NINGUN BANCO SE COJA LAS MANOS. LOS QUE SE TIENEN QUE PREOCUPAR SON LOS QUE TIENEN DÉPÓSITOS Y FONDOS EN BANCOS DE DUDOSA ACTIVIDAD. LA GENTE SE PIENSA QUE PORQUE LES DEN UN 7% YA ES UN GRAN BANCO Y SE EQUIVOCAN. LO QUE LES PASA ES QUE EL BANCO DE ESPAÑA LES PRESTA EL DINERO MAS CARO Y POR ESO OPTAN POR CONSEGUIRLO EN EL MERCADO MONETARIO, Y SI EL BANCO DE ESPAÑA NO SE FIA DE ELLOS, VA Y SE FIA LA GENTE. QUE LOS BANCOS NOES LA ADMON PUBLICA, ABRAN OS OJOS.
Hola , cuando vallais al banco queos dejen lo que hay que pagar de irpf y de iva sobre el valor de la tele ya que en la mayoria de bancos esto no lo dicen y luego llagan las sorpresas .A mi ya me ha pasado con la promoción del portatil y nunca me hablaros de esto . Cuidado
Yo he estado calculando y la tele entre unas cosas y otras te sale sobre unos 250euros que tampoco regalan tanto .Hay oficinas en las que han dado la occión de poner un dinero a plazo fijo a 12meses de 9300euros o 6800euros a 18 meses.
No es ningún chollo. Te obligan a contratar dos tarjetas de crédito que tienes que pagar porque las tienes que mantener 13 meses por lo menos y además llevan unos costes desproporcionados si las utilizas. En total, no usando las tarjetas y anulándolas una vez cumplidos los 13 meses puedes ahorrar unos 38 euros con respecto al precio de ese televisor en una gran superficie. Y además luego vendrá que te cobran para hacienda la retención correspondiente, por lo que probablemente incluso en las mejores condiciones te cueste más que si ahorras un poco y lña compras directamente.
Creó que teneis toda la razón, que aqui no te regalan nada, ya que a mí me paso con unas sartenes que regalaban el banco bilbao, que al final entre el irpf y el descuento de Hacienda, al final me salieron caras, así es que no os tomen el pelo, que al final siempre esta la letra pequeña que es la que nos joroba, por no decir otra cosa.
Yo saque el portatil y ahora me he sacado la TV LCD 32. Estas promos no hay que declararlas. No es obligado domiciliar nomina. Si, meter en la cuenta 800€ todos los meses en un margen de 10 dias. Cero matacero, pero cero,cero, cero de gastos de mantenimiento, ni por recibos, ni por el correo a casa, ni por transfer. Las tarjets gratis el 1er año. Resto fuera. Dadas de baja Menos la de debito. Banesto no pierde nada, ganar, gana clientes que es el proposito de esta promo. Precio de portatil y tv 32 en mercao unos 900€ los 2. En banest 197€. Los hay mejores, nos ha jodio! portatiles a 1200€, TV LCD 32 a 1000€. Señores, son lentejas. Relacion calida-precio-promo es cojonud…….Un saludit a los viandantes.
hola , no se si llegara mi comentario pero os voi a esplicar. esto es el cuento de la abuela. mira yo tengo el portatil. y he cogio tab la tele, pero sabeis ke?, me ha pasado de todo. os esplico. primero me cobran 74 euros y 25 euros de unas tarjetas que yo no las he visto aparecer por mi casa , me cabreo con el banco. llamo y pido esplicaciones. me dicen que van en la promocion, nunca jamas nadie me informo de las tarjetas, no me devuelven el dinero. me cabreo y me dicen que llame aun numero de tefono para darlas de baja, se pasan los dias, intentamos darlas de baja. largas y larga, que si este numero de tefono que si el otro bla bla bla. conseguimos hablar y nos dicen que tenemos que cambiar el contrato a tarifa plana o no se ke historias, llamando al banco se pasan los dias, largas y largas. me cabreo y estoi por suspender todo, me dicen que si lo quiero cambiar y dar de baja las tarjetas que nunca he tenido. tengo que pagar comisiones cada seis meses de doce y pico euros, y que si no quiero que me cobren comisiones tengo que ir todos los meses al banco a hacerlo yo, ufffffffffff.aun hay mas. me dan de baja y me hacen la tarifa plana, se equivocan un monton de veces. me hacen pasar muchos cabreos.y al final cuando llego a casa me han cobrado 25, 50 euros. y llamo por telefono y se lo digo , me dicen claro por dar de baja la otra cuenta , la madre que los pario. ladrones. o sea os digo que la tele no sale regalada, se la cobran y muy bien cobrada , nadie da nada por nada. en cuento termine de pagar lo que debo quito todas las cuentas del banesto.espero que alguien me lea y que me conteste gracias .
Banesto ha jodido a mi marido y a un amigo tambien. Para mi, despues de Banco de Andalucía son los peores. Y quieran creerlo o no ni la television ni el portátil te lo regalan.. como no cumplas cualquiera de las reglas te sancionan con 300 y pico de euros.. porque nos hemos mudado de casa y los recibos domiciados se cortaron «temporalmente» la sancion fue de mas de 300 euros.. y el cabreo q te llevas cuando ves lo q te han descontado y luego para ir a reclamarlos.. y como te tratan !! en fin.. espero que Banesto sea lo primero en undirse en el fin del mundo!!
CHOLLO!!!!!!!!!JAJAJAJAJA…….NO ES NINGUN CHOLLO!!!!!!! te cobran 100 € de gastos de manipulacion, mas 150 € en tarjetas durante 2 años, mas 6 € mensuales de mantenimiento de cuenta durante 30 meses, total que pagas 630 Euros por un ordenador o una TV que su valor seguro que no llega a 500 €. Y encima si vas a cancelar la cuenta cuando cumples los 30 meses requeridos te hacen esperar dos horas para decirte que no tienen linea de telefono para dar de baja la cuenta, cosa que no para nunca cuando vas a contratarlo. Y del trato que dispensan….., es el mismo que si vas con un fajo de billetes de 500 € por los CO-JONES
Banesto «premia», menuda falacia…
No hay ningún banco que premie a nadie.
BANESTO NECESITA NUESTRAS NÓMINAS, Y EN CUANTO VAS UN POCO JUSTO, COMO BUENOS JUDÍOS Y ÁVAROS QUE SON, TE ACOSAN Y MACHACAN, Y TE SACAN HASTA LAS ENTRAÑAS EN COMISIONES.
DESPUÉS EL ESTADO APOYA A LOS BANCOS, CON LA EXCUSA DE QUE SI CAEN LOS BANCOS CAEMOS TODOS. LOS BANCOS NECESITAN UN BOICOT DE VEZ EN CUANDO, PARA QUE NO NOS RESTREGUEN POR LA CARA SUS BENEFICIOS.
POR CIERTO, LO QUE MÁS FASTIDIA A UN BANCO ES UNA RECLAMACIÓN EN LA OFICINA DEL CONSUMIDOR Y OTRA AL BANCO DE ESPAÑA.
ES POR DAR PISTAS…